

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 5, 2008 (use as many sheets as necessary)				Application Number 10/580,458 Filing Date 10/26/2005 First Named Inventor William VAINCHENKER Art Unit 1617 Examiner Name Unassigned	Attorney Docket Number 065691-0445
Sheet	1	of	2		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
B1	3,914,359	00-22-1999	COLEMAN, R.		
		DUPLICATE			

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code ² (if known)			
B2	11/934,359		11/02/2007	Vainchenker, William	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
B3		CHLOE, JAMES, et al., "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera" NATURE (LONDON), vol. 434, no. 7037, April 2005 (2005-04), pages 1144-1148, XP002369147 ISSN: 0028-0836.	
B4		BAXTER, E. J., et al., THE CANCER GENOME PROJECT "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders" LANCET THE, LANCET LIMITED. LONDON, GB, vol. 365, no. 9464, 19 March 2005 (2005-03-19), pages 1054-1061, XP004798459 ISSN: 0140-6.	
B5		UGO, V., et al.; "Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera" EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 32, no. 2, February 2004 (2004-02), pages 179-187, XP002324352 ISSN: 0301-472X.	
B6		SALTZMAN, ALAN, et al.; "Cloning and characterization of human Jak-2 kinase: High mRNA expression in immune cells and muscle tissue" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 246, no. 3, 29 May 1998 (1998-05-29), pages 627-633, XP002324351 ISSN: 0006-291X.	

Examiner Signature	/Sheridan Swope/	Date Considered	09/25/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./
NASH_2373318.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 5, 2008 <i>(use as many sheets as necessary)</i>				Application Number 10/580,458 Filing Date 10/26/2005 First Named Inventor William VAINCHENKER Art Unit 1617 Examiner Name Unassigned Attorney Docket Number 065691-0445	
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	B7	PAHL, H. L.; "TOWARDS A MOLECULAR UNDERSTANDING OF POLYCYTHEMIA RUBRA VERA" EUROPEAN JOURNAL OF BIOCHEMISTRY, Berlin, Germany, vol. 267, no. 12, June 2000 (2000-06), pages 3395-3401, XP000982035 ISSN: 0014-2956.		
	B8	JONES, A.V., et al., "Widespread Occurrence of the JAK2 V617F Mutation in chronic Myeloproliferative Disorders," BLOOD (WASHINGTON, DC) 106 (6): 2162-12168 (2005).		
	B9	LEVINE, R. L., et al., "Activating Mutation in the Tyrosine Kinase JAK2 in Polycythemia Vera, Essential Thrombocythemia and Myeloid Metaplasia with Myelofibrosis," CANCER CELL. 2005; 7: 387-397.		
	B10	KRALOVICS, R., et al., "A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders," N ENGL J MED 2005; 352:1779-1790, Apr 28, 2005.		
	B11	ZHAO R., XING S., LI Z., et al., Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280:22788-92.		
	B12	PCT/EP2005/055586, An International Search Report/Written Opinion (English Translation).		
	B13	FR 200411480, Inpadoc report (July 25, 2007).		
	B14	FR 200411480, Derwent report (July 25, 2007).		
	B15	DATABASE UniProt [Online] 7 June 2005 (2005-06-07), "Janus kinase 2." XP002369149 extrait de EBI accession no. UNIPROT:Q506Q0 Database accession no. Q506Q0 PLUS Commercial Vendor Search of (SEQ ID NOS 1 and 3-12) summarized in a chart which contains a list of the alignments from DGENE, USGENE and Registry (PCTGEN and NCBI contained no unique results), by the STN accession number, the homology score, the assignee/corporate source, the title of the patent/article, the patent number/journal information, and the publication date.		
	B16	JAK2 GeneCard (genecards.org/cgi-bin/cardisp.pl ?gene=JAK2&search=jak2\$suff=txt, 12/27/07, pages 1-17.=).		
	B17	ROSSI et al., Leukemia Research, 2007, vol. 31, pp. 97-101.		
	B18	TEFFEN et al., Leukemia Research, 2006, vol. 30, pp. 739-744.		

Examiner Signature	/Sheridan Swope/	Date Considered	09/25/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.S./
 WASH_2373318.1